- Volume 15 Issue 21
Background: Patients with refractory or relapsed multiple myeloma are considered to have a very poor prognosis, and new regimens are needed to improve the outcome. Gemcitabine, a nucleoside antimetabolite, is an analog of deoxycytidine which mainly inhibits DNA synthesis through interfering with DNA chain elongation and depleting deoxynucleotide stores, resulting in gemcitabine-induced cell death. Here we performed a systemic analysis to evaluate gemcitabine based chemotherapy as salvage treatment for patients with refractory and relapsed multiple myeloma. Methods: Clinical studies evaluating the impact of gemcitabine based regimens on response and safety for patients with refractory and relapsed multiple myeloma were identified by using a predefined search strategy. Pooled response rate (RR) of treatment were calculated. Results: In gemcitabine based regimens, 3 clinical studies which including 57 patients with refractory and relapsed multiple myeloma were considered eligible for inclusion. Systemic analysis suggested that, in all patients, pooled RR was 15.7% (9/57) in gemcitabine based regimens. Major adverse effects were hematologic toxicity, including grade 3 or 4 anemia, leucopenia and thrombocytopenia i. No treatment related death occurred with gemcitabine based treatment. Conclusion: This systemic analysis suggests that gemcitabine based regimens are associated with mild activity with good tolerability in treating patients with refractory or relapsed multiple myeloma.
Multiple myeloma;relapsed/refractory cases;chemotherapy;gemcitabine
- Attal M, Harousseau JL, Stoppa AM, et al (1995). Highdose chemotherapy in multiple myeloma: a prospective randomized study of the "Intergroupe Francais du Myelome" (IFM). Vth International Workshop on Multiple Myeloma 1995, La Baule, France.
- Barlogie B, Smith L, Alexanian R (1984). Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med, 310, 1353-6. https://doi.org/10.1056/NEJM198405243102104
- Fernand JP, Levy Y, Gerota J, et al (1989). Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood, 73, 20-3.
- Bjorkstrand B (1995). 474 autotransplants in multiple myeloma-results of the EBMT. Vth International Workshop on Multiple Myeloma 1995; September 10-13: La Baule, France.
- Braakhuis BJ, van Dongen GA, Vermorken JB, et al (1991). Preclinical in vivo activity of 2', 2'-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res, 51, 211-4.
- Gazitt Y1, Shaughnessy P, Rothenberg ML, et al (2006). A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients. Oncol Rep, 16, 877-84.
- Gay F, Larocca A, Wijermans P, et al (2011). Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients. Blood, 117, 3025-31. https://doi.org/10.1182/blood-2010-09-307645
- Kumar SK, Rajkumar SV, Dispenzieri A, et al (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-20. https://doi.org/10.1182/blood-2007-10-116129
- Kyle RA, Child JA, Anderson K, et al (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol, 121, 749-57. https://doi.org/10.1046/j.1365-2141.2003.04355.x
- Lilenbaum RC, Green MR (1993). Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol, 11, 1391-402.
- Moore DF Jr, Pazdur R, Daugherty K et al (1992). Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs, 10, 323-5. https://doi.org/10.1007/BF00944189
- Offidani M, Mele A, Corvatta L, Marconi M et al (2002). Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma. Leuk Lymphoma, 43, 1273-9. https://doi.org/10.1080/10428190290026330
- Palumbo A, Anderson K (2011). Multiple myeloma. New Engl J Med, 364, 1046-60. https://doi.org/10.1056/NEJMra1011442
- Sun TT, Wang JL, Fang JY (2013). Gemcitabine alone or in combination with cisplatin for advanced biliary tract carcinomas: an overview of clinical evidence. Asian Pac J Cancer Prev, 14, 877-83. https://doi.org/10.7314/APJCP.2013.14.2.877
- Su A, Zhang J, Pan ZH, et al (2013). Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer. Asian Pac J Cancer Prev, 14, 1841-6. https://doi.org/10.7314/APJCP.2013.14.3.1841
- Wang M, Gu J, Wang HX, et al (2012). Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. Asian Pac J Cancer Prev, 13, 4153-6. https://doi.org/10.7314/APJCP.2012.13.8.4153
- Wei MY, Zhuang YF, Wang WM (2014). Gemcitabine for the treatment of patients with osteosarcoma. Asian Pac J Cancer Prev, 15, 7159-62. https://doi.org/10.7314/APJCP.2014.15.17.7159
- Weick JK1, Crowley JJ, Hussein MA, et al (2002). The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study. Invest New Drug, 20, 117-21. https://doi.org/10.1023/A:1014493007347
- Yuan SF, Zhang LP, Zhu LJ, et al (2013). Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer. Asian Pac J Cancer Prev, 14, 3949-53. https://doi.org/10.7314/APJCP.2013.14.6.3949
- Pooled Analysis of Pomalidomide for Treating Patients with Multiple Myeloma vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3163